Innophos Announces EU REACH Registration for INNOVALT® SL70 Scavenger
27.3.2024 18:58:00 EET | Business Wire | Press release
Innophos, a leading global producer of specialty phosphates and minerals, proudly announces the EU REACH registration of its groundbreaking product, INNOVALT® SL70 Scavenger. This achievement underscores Innophos' dedication to innovation, human health, and environmental sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240327530810/en/
INNOVALT® SL70 Scavenger by Innophos Receives EU REACH Registration (Photo: Business Wire)
INNOVALT® SL70 Scavenger, a patented formula, significantly reduces the release of toxic hydrogen sulfide (H2S) in the production, storage, and application of bitumen. By improving workplace safety and reducing environmental pollution, INNOVALT® SL70 Scavenger exemplifies Innophos' commitment to creating healthier communities and work environments.
Additionally, INNOVALT® SL70 Scavenger enhances the longevity of equipment by minimizing corrosion. This benefit, coupled with its compatibility with polyphosphoric acid and other common bitumen additives, positions INNOVALT® SL70 as a versatile, user-friendly solution suitable for a wide range of bitumen types.
John Toczek, VP of Business Management at Innophos, expressed his enthusiasm: "The EU REACH registration of INNOVALT® SL70 Scavenger is a testament to our dedication to the European Union's rigorous safety and regulatory standards. It also reflects our commitment to delivering superior safety and performance-enhancing solutions to the EU bitumen industry."
INNOVALT® SL70 Scavenger not only meets but sets new industry benchmarks for environmental stewardship and operational excellence in the bitumen sector.
For further details on INNOVALT® SL70 Scavenger and its advantages, please visit our website.
About Innophos
Innophos is a leading global producer of specialty phosphate and mineral solutions serving food, beverage, nutrition, and industrial markets. Leveraging our expertise in phosphate science and technology, we partner with our customers to innovate and deliver products that excel in quality and performance. Headquartered in Cranbury, New Jersey, Innophos has an integrated manufacturing footprint that spans the United States, Canada, Mexico, and China. For more information, please visit www.innophos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327530810/en/
Contact information
Carrie Livingston
Email: carrie@colinkurtis.com
Phone: 815-519-8302
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Teamily AI Reports 32× Quarterly User Growth, Positive Gross Margins, and Strong Global Adoption of Human–Agent Collaboration3.11.2026 15:00:00 EET | Press release
Teamily AI, a human–agent collaboration platform that enables people and AI agents to work together in a unified, context-aware workspace, today announced significant growth and commercial milestones following a quarter of rapid global expansion. The company grew from 10,000 to 320,000 sign-ups in a single quarter, a 32× increase that works out to a compound monthly growth rate of 217.5%, just three months after its public launch in July 2026. With positive gross margins on paying users, and growing adoption among professional teams and businesses, Teamily AI establishes a foundation for scalable product-led growth (PLG). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103047955/en/ 32× Global Growth in One Quarter Teamily AI grew from 10,000 to 320,000 registered users across more than 100 countries in one quarter, representing 32× growth and a 217.5% compound monthly growth rate. According to publicly available Similarwe
Fourthline and Veridas Complete Merger to Create a European Leader in Bank-Grade Digital Identity3.11.2026 14:40:00 EET | Press release
Fourthline and Veridas today announce the completion of their merger, first announced on 16 July 2026. The transaction closed on 3 November 2026 following the satisfaction of all closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103282546/en/ The funding will be used to accelerate product innovation, pursue strategic M&A, refinance debt, and support a shareholding reorganization that includes partial liquidity for Veridas shareholders. Both businesses will be EBITDA-positive at close. The combination is expected to deliver €20m in annual run-rate synergies. With limited customer overlap and complementary markets, most of that growth will come from offering each company's proprietary technology underpinning the full scope of IDV products to the other's customers. Leadership and governance Fourthline CEO, Paul Stoddart, will lead the combined entity as Chief Executive Officer. Finch Capital Managing Partner
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights3.11.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the third quarter 2026 financial results and business highlights. "Compass is leading one of the most important advances in mental health care in decades. Millions of people living with TRD are waiting for new treatments that can deliver meaningful and lasting benefit, and we believe COMP360 has the potential to change the paradigm," said Kabir Nath, Chief Executive Officer of Compass Pathways. “With the imminent completion of our NDA submission and the potential for a quick approval, we are executing with urgency and discipline to launch this much needed treatment in the first half of 2027. At the same time, we continue to advance our PTSD program, extending the potential impact of COMP360 to additional patient populations with significant unmet need. With a robust clinical package, a clear path forward, and a launch-ready orga
Vedanta Limited Delivers Highest-ever Half-yearly Profit of $1.21 bn, up 151% YoY3.11.2026 13:26:00 EET | Press release
Indian multinational Vedanta Limited (BSE: 500295 & NSE: VEDL), a global leader in metals and critical minerals, announced its consolidated results for the second quarter and half year ended 30 September 2026, delivering its best-ever financial performance driven by operational excellence and disciplined execution. Vedanta Limited achieved its highest-ever quarterly Profit of $649 mn, up 151% YoY, while half-yearly Profit reached a record $1.21 bn, up 151% YoY. Vedanta also declared its first interim dividend of INR 5 per share during the quarter, reinforcing its commitment to shareholder returns. The Company delivered record quarterly revenue of $2.70 bn, up 57% YoY, taking half-yearly revenue to a record $5.18 bn, up 54% YoY. Quarterly EBITDA surged 106% YoY to $1.04 bn, while half-yearly EBITDA reached a record $1.94 bn, up 103% YoY. EBITDA margins expanded to 60% in Q2 and 58% in H1, improving by 1,055 bps and 1,023 bps YoY, respectively. Vedanta further strengthened its balance sh
BeOne Medicines to Present at the Jefferies Global Healthcare Conference3.11.2026 13:01:00 EET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, with a fireside chat at 9:30 a.m. GMT. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom